We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
First Novel Compound Library Designed to Target DUB Enzymes Released
Product News

First Novel Compound Library Designed to Target DUB Enzymes Released

First Novel Compound Library Designed to Target DUB Enzymes Released
Product News

First Novel Compound Library Designed to Target DUB Enzymes Released


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "First Novel Compound Library Designed to Target DUB Enzymes Released "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

To mark the launch of the library Dr John Harris (Ubiquigent Scientific Advisory Board member) will be presenting DUBtarget™-001 at the Society of Chemical Industry (SCI) conference – Innovation in design, supply and acquisition for compound screening libraries. 

Ubiquigent, in collaboration with the Drug Discovery Unit (DDU) at the University of Dundee, have jointly developed the library to support both commercial and academic researchers looking to either enter the ubiquitin drug discovery field or to support those with active programmes but who are seeking access to additional chemical diversity.

The design of DUBtarget™-001 (led by Dr Andrew Woodland of the DDU) has been informed by DUB-related structural data to yield a library with the potential to have activity across multiple DUB families.  Ubiquigent has already screened the library against USP2 (a DUB with potential roles in oncology) and demonstrated a significant number of hits from different structural classes.  These structures represent multiple starting points with the potential to lead to the development of novel therapeutic and tool compounds.  

The library is now available in either its physical form for screening within researchers’ own laboratories or as a dataset where the library will be screened against any of the 40 other DUB enzymes included within Ubiquigent’s DUBprofiler™ screening platform.  

Advertisement